Christian Confavreux

Overview

Best Publications

• Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

  Richard A. Rudick;William H. Stuart;Peter A. Calabresi;Christian Confavreux

  1661
  Citations

• Development of a multiple sclerosis functional composite as a clinical trial outcome measure

  Gary R. Cutter;Monika L. Baier;Richard A. Rudick;Diane L. Cookfair

  1444
  Citations

• Early Clinical Predictors and Progression of Irreversible Disability in Multiple Sclerosis: an Amnesic Process

  Christian Confavreux;Sandra Vukusic;Patrice Adeleine

  1330
  Citations

• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

  Jeffrey A. Cohen;Alasdair J. Coles;Douglas L. Arnold;Christian Confavreux

  1292
  Citations

• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

  Alasdair J. Coles;Cary L. Twyman;Douglas L. Arnold;Jeffrey A. Cohen

  1290
  Citations

• Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

  Paul O'Connor;Jerry S Wolinsky;Christian Confavreux;Giancarlo Comi

  1237
  Citations

• Course and Prognosis of Multiple Sclerosis Assessed by the Computerized Data Processing of 349 Patients

  C. Confavreux;G. Aimard;M. Devic

  697
  Citations

• Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

  Christian Confavreux;Paul O'Connor;Giancarlo Comi;Mark S. Freedman

  672
  Citations

• Vaccinations and the Risk of Relapse in Multiple Sclerosis

  Christian Confavreux;Samy Suissa;Patricia Saddier;Valérie Bourdès

  631
  Citations

• Natural History of Multiple Sclerosis with Childhood Onset

  Christel Renoux;Sandra Vukusic;Christian Confavreux

  623
  Citations

• Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

  G Edan;D Miller;M Clanet;C Confavreux

  572
  Citations

• Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

  Richard Rudick;Jack Antel;Christian Confavreux;Gary Cutter

  464
  Citations

• A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

  P W O'Connor;D Li;M S Freedman;A Bar-Or

  438
  Citations

• The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL

  P. A. Calabresi;G. Giovannoni;C. Confavreux;S. L. Galetta

  408
  Citations

• Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum

  Giovanni Stevanin;Filippo M. Santorelli;Hamid Azzedine;Hamid Azzedine;Paula Coutinho

  401
  Citations

• First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability.

  Yann Mikaeloff;Samy Suissa;Louis Vallée;Catherine Lubetzki

  388
  Citations

• Secondary progressive multiple sclerosis: current knowledge and future challenges

  Marco Rovaris;Christian Confavreux;Roberto Furlan;Ludwig Kappos

  385
  Citations

• Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial:

  Patrick Vermersch;Anna Czlonkowska;Luigi M E Grimaldi;Christian Confavreux

  381
  Citations

• EDMUS, a European database for multiple sclerosis.

  C. Confavreux;D. A. S. Compston;O. R. Hommes;W. I. Mcdonald

  361
  Citations

• Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

  J. Kuhle;G. Disanto;R. Dobson;R. Adiutori

  353
  Citations